Patents
Literature
2 results about "Antigenic variation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.
A method for detecting anti-preS1 antibody, a kit for detecting anti-preS1 antibody and application thereof
The application relates to a detection method of anti-preS1 antibody, an anti-preS1 antibody detection kit and application, the application carries out multi-sequence comparison and conservation analysis on preS1 sequences of different genotypes (A, B, C, D and CD mixed type) of HBV, takes type A (AB697487.1), type C (FJ032351.1) and type D (LC519808.1) as reference sequences, based on the sequence consistency standard of 85% of full length and 90% of the key region of functional antibody binding, a highly conservative preS1 full-length antigen sequence is systematically screened out in natural variation, the sequence can cover antigen variation of A-D type HBV, and the sequence is taken as a coating antigen to establish an indirect ELISA detection system, a good linear relationship is presented in the range of 4.88-625 ng / mL, and the Cut-off value is 33.6 ng / mL; clinical verification shows that the method can effectively distinguish chronic hepatitis B patients from healthy control groups, compared with detection methods based on partial fragments or overlapping short fragments, the false negative rate can be significantly reduced, and the method is suitable for HBV infection immune state evaluation, anti-virus curative effect monitoring and prognosis analysis.
Owner:FUDAN UNIVERSITY
A class of fully human antibodies that inhibit the neuraminidase activity of H3N2 influenza virus and their applications
This invention relates to a class of fully human antibodies that inhibit the neuraminidase activity of H3N2 influenza virus and their applications, belonging to the field of biomedical technology. Addressing the shortcomings of existing technologies, such as the susceptibility of H3N2 subtypes of influenza A virus to antigenic mutations, the tendency for traditional small-molecule drugs to develop resistance, and the narrow protective spectrum of existing antibody drugs, this invention provides a class of fully human antibodies that recognize the same epitope group and inhibit the neuraminidase activity of H3N2 influenza virus. The CDR regions of these fully human antibodies exhibit high overall similarity, establishing a conserved antibody-binding backbone. Simultaneously, their heavy chain variable region CDR3 exhibits specific sequence variations, forming a structural feature of "conserved backbone + variant HCDR3". The fully human antibodies provided by this invention have low immunogenicity risk and broad application prospects in the prevention, treatment, and related diagnostic reagents and test kits for H3N2 influenza.
Owner:WESTLAKE UNIV